哈尔滨医科大学附属第一医院
First Affiliated Hospital of Harbin Medical University
在本站收录的 53 种疾病中,这家医院列在其中 16 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
哈尔滨医科大学附属第一医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肝细胞癌Hepatocellular carcinoma31 篇牵头论文
- 肝母细胞瘤Hepatoblastoma0 篇牵头论文
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 骨肉瘤Osteosarcoma21 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma3 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma4 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
- 烟雾病Moyamoya disease2 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis11 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy2 篇牵头论文
- 先天性巨结肠Hirschsprung disease1 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、脊索瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 31 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文31
- A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.
- Periodontitis and Hepatocellular Carcinoma: A Two-Sample Mendelian Randomisation Study.
- Melanin@PLGA/Nuciferine Nanoparticles for Enhanced Photothermal Therapy of Hepatocellular Carcinoma by Promoting Autophagy.
- Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.
- DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma.
- RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinoma.
- FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity.
- Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC.
- RRP8, associated with immune infiltration, is a prospective therapeutic target in hepatocellular carcinoma.
- Integrative transcriptome analysis identifies a crotonylation gene signature for predicting prognosis and drug sensitivity in hepatocellular carcinoma.
- A TiN-based nanophotosensitizer for enhanced photothermal therapy with the aid of ultrasound.
- Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma.
- Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
- TMEM147 aggravates the progression of HCC by modulating cholesterol homeostasis, suppressing ferroptosis, and promoting the M2 polarization of tumor-associated macrophages.
- Triptonide inhibits growth and metastasis in HCC by suppressing EGFR/PI3K/AKT signaling.
- Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.
- RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway.
- Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
- Cytochrome B5 type A alleviates HCC metastasis via regulating STOML2 related autophagy and promoting sensitivity to ruxolitinib.
- Long non-coding RNA TPTEP1 exerts inhibitory effects on hepatocellular carcinoma by impairing microRNA-454-3p-mediated DLG5 downregulation.
- ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.
- Impact of concurrent splenectomy and esophagogastric devascularization on surgical outcomes of partial hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: A multicenter propensity score matc
- Identification of CFHR4 as a Potential Prognosis Biomarker Associated With lmmune Infiltrates in Hepatocellular Carcinoma.
- Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
- Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
- Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.
- TNF-α/NF-κB signaling epigenetically represses PSD4 transcription to promote alcohol-related hepatocellular carcinoma progression.
- Postoperative morbidity adversely impacts long-term oncologic prognosis following hepatectomy for hepatocellular carcinoma: A multicenter observational study.
- CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.
- The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma.
- Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在肝母细胞瘤下全国有 86 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 2 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 6 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文21
- Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy.
- Harmine exerts anticancer effects through the ROS/p38 axis to induce autophagy and apoptosis in osteosarcoma.
- Extraskeletal Ewing Sarcoma of the Abdominopelvic Cavity Revealed by 18 F-FDG PET/CT.
- A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia.
- Antitumor effects of cannabidiol (CBD) on osteosarcoma by targeting TNF-α/NF-κB/CCL5 signaling axis.
- NAT10 mediated ac4C acetylation driven m6A modification via involvement of YTHDC1-LDHA/PFKM regulates glycolysis and promotes osteosarcoma.
- A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma.
- M7G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma.
- Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis.
- Integration of single-cell sequencing and bulk expression data reveals chemokine signaling pathway in proliferating cells is associated with the survival outcome of osteosarcoma.
- RING finger gene 180 inhibits osteosarcoma progression through regulating chromobox homolog 4 ubiquitination.
- PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.
- Bevacizumab attenuates osteosarcoma angiogenesis by suppressing MIAT encapsulated by serum-derived extracellular vesicles and facilitating miR-613-mediated GPR158 inhibition.
- The Subcellular Localization of IncRNA FAM230B in Osteosarcoma and Its Interaction with Early miR-203.
- LncRNA BACE1-AS promotes the progression of osteosarcoma through miR-762/SOX7 axis.
- Hydroxygenkwanin suppresses proliferation, invasion and migration of osteosarcoma cells via the miR‑320a/SOX9 axis.
- Involvement of miR-769-5p/Retinoic Acid Receptor Responder 1 Axis in the Progression of Osteosarcoma: Characterization of Potential Therapeutic Targets.
- Accurate Identification and Early Diagnosis of Osteosarcoma through CRISPR-Cas12a-Based Average Telomerase Activity Detection.
- Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
- NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway.
- Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.
早期论文(2016–2020 年)26
- Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma.
- Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p.
- Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
- Construction and Validation of Nomograms for Predicting the Prognosis of Juvenile Osteosarcoma: A Real-World Analysis in the SEER Database.
- NFIL3 Acts as a Nuclear Factor to Increase Osteosarcoma Progression.
- Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma.
- Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p.
- Synergistic anti-tumor effects of arsenic trioxide and blue LED irradiation on human osteosarcoma.
- SIRT1-ZEB1-positive feedback promotes epithelial-mesenchymal transition process and metastasis of osteosarcoma.
- Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells.
- miR-590-3p is a novel microRNA which suppresses osteosarcoma progression by targeting SOX9.
- Chimaphilin inhibits human osteosarcoma cell invasion and metastasis through suppressing the TGF-β1-induced epithelial-to-mesenchymal transition markers via PI-3K/Akt, ERK1/2, and Smad signaling pathways.
- Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma.
- Construction and analysis of a ceRNA‑ceRNA network reveals two potential prognostic modules regulated by hsa‑miR‑335‑5p in osteosarcoma.
- MicroRNA-129-5p suppresses cell proliferation, migration and invasion via targeting ROCK1 in osteosarcoma.
- Deoxyelephantopin Induces Reactive Oxygen Species-Mediated Apoptosis and Autophagy in Human Osteosarcoma Cells.
- A novel mechanism of mTORC1-mediated serine/glycine metabolism in osteosarcoma development.
- MicroRNA-492 overexpression exerts suppressive effects on the progression of osteosarcoma by targeting PAK7.
- Berberine affects osteosarcoma via downregulating the caspase-1/IL-1β signaling axis.
- Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells.
- Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma.
- A single nucleotide polymorphism in the 3'-untranslated region of the KRAS gene disrupts the interaction with let-7a and enhances the metastatic potential of osteosarcoma cells.
- Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.
- Relationship Between P15 Gene Mutation and Formation and Metastasis of Malignant Osteosarcoma.
- Long noncoding RNA FGFR3-AS1 promotes osteosarcoma growth through regulating its natural antisense transcript FGFR3.
- MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
早期论文(2016–2020 年)3
- Analysis of risk factors of gastrointestinal stromal tumors in different age groups based on SEER database.
- Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 7 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- Single cell analysis reveals the roles and regulatory mechanisms of type-I interferons in Parkinson's disease.
- KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1.
- LncRNA nuclear-enriched abundant transcript 1 aggravates cerebral ischemia/reperfusion injury through activating early growth response-1/RNA binding motif protein 25 axis.
早期论文(2016–2020 年)3
- Ubiquitin-specific protease 22 is associated with poor prognosis in neuroblastoma.
- Upregulation of miR-34a by Inhibition of IRE1α Has Protective Effect against Aβ-Induced Injury in SH-SY5Y Cells by Targeting Caspase-2.
- Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative stress and modulates α-synuclein expression.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 3 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Risk Stratification and MRD-driven Maintenance for MM After ASCT
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06697483
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院;另有 2 家列出的医院为研究中心北京、哈尔滨
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- Adhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma.
- Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis.
- Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis.
- Mechanism of exosomal miR-155 derived from bone marrow mesenchymal stem cells on stemness maintenance and drug resistance in myeloma cells.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
这些数字背后的记录
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
哈尔滨有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Registry of Multicenter Brain-Heart Comorbidity in China
- 分期
- 未注明
- 开始
- 2012-01
- 登记号
- NCT05961748
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 3 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- Retrospective Study of Effect of Fine Particulate Matter on Acute Exacerbation of Patients with Idiopathic Pulmonary Fibrosis.
- Lung myofibroblast transition and fibrosis is regulated by circ0044226.
- Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文11
- COMM domain containing 4 inhibits hephaestin and ferroportin to enhance neuronal ferroptosis by disturbing the Cu-Fe balance in amyotrophic lateral sclerosis.
- Inhibition of Salt-Inducible Kinase 2 Protects Motor Neurons From Degeneration in ALS by Activating Autophagic Flux and Enhancing mTORC1 Activity.
- Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.
- Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation.
- DAPK1 induces motor neuron apoptosis in hSOD1G93A-linked amyotrophic lateral sclerosis via regulating the Xiap/JNK pathway.
- Multi-omics framework integrating genetics microbiome and immunity for understanding motor neuron degeneration pathogenesis.
- RBM5 induces motor neuron apoptosis in hSOD1G93A-related amyotrophic lateral sclerosis by inhibiting Rac1/AKT pathways.
- Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis.
- BRD7 regulates cellular senescence and apoptosis in ALS by modulating p21 expression and p53 mitochondrial translocation respectively.
- SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1.
- Diphenyl diselenide protects motor neurons through inhibition of microglia-mediated inflammatory injury in amyotrophic lateral sclerosis.
早期论文(2016–2020 年)8
- Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
- Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3β/Nrf2/GCLC pathways.
- Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage.
- γ-Oryzanol mitigates oxidative stress and prevents mutant SOD1-Related neurotoxicity in Drosophila and cell models of amyotrophic lateral sclerosis.
- α-Lipoic acid attenuates oxidative stress and neurotoxicity via the ERK/Akt-dependent pathway in the mutant hSOD1 related Drosophila model and the NSC34 cell line of amyotrophic lateral sclerosis.
- Fisetin Exerts Antioxidant and Neuroprotective Effects in Multiple Mutant hSOD1 Models of Amyotrophic Lateral Sclerosis by Activating ERK.
- Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.
- Comparative Analysis of VOCs in Exhaled Breath of Amyotrophic Lateral Sclerosis and Cervical Spondylotic Myelopathy Patients.
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 2 家医院列在白塞病下全国有 139 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 4 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
哈尔滨有 1 家医院列在先天性巨结肠下全国有 76 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
联系这家医院
出示给工作人员或司机的院名卡
哈尔滨医科大学附属第一医院
First Affiliated Hospital of Harbin Medical University
哈尔滨
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药